Properties
What is it?
Composition: Vial with lyophilized powder as active substance contains: Hydroxocobalamin 10 mg. Excipients: Mannitol, Hydrochloric acid. Ampoule with solvent as active substance contains: Potassium diclofenac 75 mg, Betamethasone sodium phosphate 2.63 mg. Excipients: Benzyl alcohol, anhydrous disodium phosphate, propylene glycol, methylparaben, sodium hydroxide, propylparaben, water for injection. Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic agents. Diclofenac, combinations. Indications: Acute exacerbations of rheumatism, inflammatory mono- and polyneuropathies. Dosage and administration: The preparation is used in adults by intramuscular injection. The contents of the vial with lyophilized powder are dissolved with the contents of the solvent ampoule. The injection is administered at intervals of several hours, 1-2 times a day, deep into the muscle. The preparation Bumanol is not used for more than 2 days. The preparation should be used at an effective dose for a short period. Contraindications: Hypersensitivity to the components of the preparation and other NSAIDs; active peptic ulcer of the stomach or duodenum; gastrointestinal bleeding or perforation, severe renal and hepatic insufficiency; decompensated heart failure; severe form of hypertensive disease; systemic fungal infections; active tuberculosis; osteoporosis; Itsenko-Cushing's syndrome; diabetes mellitus; hepatitis A, B and other viral infections; period of vaccination; pregnancy and lactation; intramuscular administration in patients with idiopathic thrombocytopenic purpura; gout; treatment with systemic anticoagulants; childhood age. Pregnancy and lactation: The preparation is contraindicated during pregnancy and lactation. Overdose: Symptoms: vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus or convulsions. In case of severe poisoning, acute renal failure and liver damage are possible. Treatment: Includes supportive measures and symptomatic treatment. Strict medical supervision of the patient's condition, maintenance of optimal fluid intake and control of electrolyte levels in serum and urine are necessary. Appearance and packaging: Reddish-pink lyophilized powder; solvent: colorless or pale pink, clear solution. Lyophilized powder for preparation of injection solution in a yellow glass vial, sealed with a bromobutyl stopper and a combined cap, in a set with the solvent in a 3 ml ampoule. 1 vial of lyophilized powder and 1 ampoule of solvent with a leaflet in a cardboard box, with a cardboard divider. Storage conditions: Store in a place protected from moisture, inaccessible to children, at a temperature not exceeding 25C. Shelf life: 3 years